HIGHLIGHTS
- who: Benjamin M. Hiller from the Ethics statements All animal procedures were performed with Institutional Animal Care and Use Committee approval from Rush University Medical Center have published the article: Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinsonu2019s disease, in the Journal: (JOURNAL)
- what: In developing the robust , clinically-compliant, mDA differentiation process, this paper examined the engraftment, innervation, and functional efficacy in hemiparkinsonian rats using cells from different developmental stages. The mDA progenitor (D17) and immature (D24) mDA neurons cannot be enriched with mitomycin C because they are still . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.